ライフサイエンスコーパス: dosimetry

1 able and more reliable than CSF sample-based dosimetry.

2 iochromic films to characterize the method's dosimetry.

3 d pediatric humans to estimate normal-tissue dosimetry.

4 imaging, tissue biodistribution studies, and dosimetry.

5 )Lu-lilotomab satetraxetan were included for dosimetry.

6 ssess pharmacokinetics, biodistribution, and dosimetry.

7 ssess pharmacokinetics, biodistribution, and dosimetry.

8 g the reliability of SPECT-based voxel-level dosimetry.

9 ondisplaceable binding potential (BPND); and dosimetry.

10 cytometry and in vivo by PET/CT imaging and dosimetry.

11 ll non-Hodgkin lymphoma were included for RM dosimetry.

12 were used to determine pharmacokinetics and dosimetry.

13 y of quantitative imaging for internal renal dosimetry.

14 of long-term toxicity studies and microscale dosimetry.

15 istribution, pharmacokinetics, and radiation dosimetry.

16 e assessment of safety, biodistribution, and dosimetry.

17 potential interest for medical and personal dosimetry.

18 d using OLINDA/EXM software to determine the dosimetry.

19 ssment and provide data essential to (177)Lu dosimetry.

20 Altogether, 13 tumors were eligible for dosimetry.

21 tumumab was safe and demonstrated acceptable dosimetry.

22 ution, pharmacokinetics, and tumor and organ dosimetry.

23 Based on subcellular dosimetry, (125)I-KX1 was approximately twice as effecti

24 On the basis of subcellular dosimetry, (125)I-KX1 was approximately twice as effecti

25 Methods: To approximate radiation dosimetry, 4 patients with metastatic castration-resista

26 fety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-trastuzumab.

27 ilable data demonstrate that posttherapeutic dosimetry after a first treatment cycle predicts the abs

28 ribution and alpha-imaging-based small-scale dosimetry, along with immunohistochemical staining.

29 SE (Fluorescent Automated Screening Tool for Dosimetry), an immunofluorescent, biomarker-based system

30 Dosimetry analysis revealed that the dose delivered by (

31 ogical Protection recommendations, radiation dosimetry analysis was performed using IDAC-Dose 2.1.

32 studies: in the first study, human radiation dosimetry and biodistribution of (11)C-metformin were es

33 discrepancy between the results of physical dosimetry and biodosimetry, which among the small number

34 review is to summarize available data on the dosimetry and dose-response relationships of several the

35 studies are needed to better understand the dosimetry and health effects of exposures to secondhand

36 peration of laser accelerator, beam shaping, dosimetry and irradiation procedure of volumetric biolog

37 8)F-PI-2620 exhibits fast kinetics, suitable dosimetry and low TRV.

38 Gafchromic film dosimetry and Monte Carlo simulations were carried out t

39 rinted light applicators with pre-calibrated dosimetry and mouth props that can be utilized to perfor

40 Twenty-one tumors were included for voxel dosimetry and parameters describing dose-volume coverage

41 This article describes the basics of CT dosimetry and PET/CT acquisition in children.

42 tially in the same subjects to ascertain the dosimetry and potential suitability of orally administer

43 dy was to assess the tracer biodistribution, dosimetry and quantitative methods of (18)F-PI-2620 in t

44 We determined its radiation dosimetry and relationships to pretherapeutic imaging an

45 ifferent image-based methods for bone marrow dosimetry and study the dose-response relationship durin

46 package to calculate the internal radiation dosimetry and the subjects' effective dose.

47 Results: Forty-two patients with complete dosimetry and therapy data were analyzed.

48 R1404 is a suitable theranostic scaffold for dosimetry and therapy with potentially broad applicabili

49 hat such NIRS methods can be used to improve dosimetry and to minimize variations of clinical outcome

50 Correlations between PSMA PET/CT parameters, dosimetry, and biochemical and therapeutic response were

51 n these promising findings, biodistribution, dosimetry, and brain kinetic modeling of (11)C-JNJ-42491

52 meters before and after treatment, radiation dosimetry, and complications were recorded.

53 8)F-PI-2620 exhibits fast kinetics, suitable dosimetry, and low TRV.

54 in applications such as particle detection, dosimetry, and medical imaging and therapy.

55 weight, placental weight, internal chemical dosimetry, and placental thyroid hormone levels were det

56 were evaluation of safety, biodistribution, dosimetry, and preliminary tumor targeting of (68)Ga-Neo

57 rement of effective radical doses by radical dosimetry, and proper normalization of the inherent reac

58 dy was to assess the tracer biodistribution, dosimetry, and quantitative methods of (18)F-PI-2620 in

59 s study was to evaluate the biodistribution, dosimetry, and safety of the HER2-specific (99m)Tc-ADAPT

60 e tumors (NETs) to evaluate biodistribution, dosimetry, and safety.

61 Safety, biodistribution, radiation dosimetry, and the most appropriate imaging time point f

62 valuation was to assess the biodistribution, dosimetry, and therapeutic efficacy of (19)F/(177)Lu-rhP

63 Biodistribution, dosimetry, and tumor uptake were quantified.

64 ating the safety, biodistribution, radiation dosimetry, and tumor-imaging potential of (131)I-GMIB-an

65 Male Sprague-Dawley rats were used to assess dosimetry, antagonistic efficacy via blood pressure meas

66 work, the 3-dimensional Voxel-Based Internal Dosimetry Application (VIDA) and 4D Extended Cardiac Tor

67 The 3-dimensional VIDA dosimetry application Monte Carlo simulation was run usi

68 each subject using the intrathecal-specific dosimetry application.

69 ontroversies regarding the role of radiation dosimetry are discussed as well.

70 PET/CT scans for dosimetry assessment were obtained at 10, 60, and 90 min

71 ingent sensitivity requirements for internal dosimetry assessment.

72 determine the biodistribution and whole-body dosimetry assessments by positron emission tomography (P

73 based on whole-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSK

74 based on whole-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSK

75 ry of (99m)Tc-MAA SPECT/CT and posttreatment dosimetry based on (90)Y time-of-flight (TOF) PET/CT.

76 n (90)Y radioembolization of HCC, predictive dosimetry based on (99m)Tc-MAA SPECT/CT provided good es

77 Microscale kidney dosimetry based on alpha-camera images and a nephron mod

78 ch is crucial for clinical implementation of dosimetry-based treatment.

79 is first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted

80 ings by a first-in-human (11)C-metformin PET dosimetry, biodistribution, and tissue kinetics study.

81 Dosimetry calculation showed that compared with (177)Lu-

82 inistration and underwent whole-body PET for dosimetry calculation.

83 tively poor spatial resolution and imprecise dosimetry calculation.

84 inistration and underwent whole-body PET for dosimetry calculation.

85 Radiation dosimetry calculations determined pharmacokinetics param

86 Dosimetry calculations found that effective doses for [(

87 Dosimetry calculations indicate promise for future (90)Y

88 Dosimetry calculations predict that 370 MBq of (51)Mn in

89 Dosimetry calculations revealed a mean effective dose of

90 Moreover, dosimetry calculations revealed that radionuclide-labele

91 Dosimetry calculations revealed that the pretargeting sy

92 Dosimetry calculations showed a tumor-absorbed dose of 4

93 d 48 h after administration and analyzed for dosimetry calculations.

94 ed and used to determine residence times for dosimetry calculations.

95 aging at 1, 2, and 3-4 h after injection for dosimetry calculations.

96 e group, pretherapeutic (124)I PET/CT lesion dosimetry can be used as a prognostic tool to predict le

97 as able to predict more realistic volumetric dosimetry compared to all other algorithms and achieved

98 dels were biased in their predicted clinical dosimetry compared to empirical values.

99 In this study, we assessed PET dosimetry data of six (18)F-labelled radiotracers using

100 moral uptake, biodistribution, and radiation dosimetry data provide strong preclinical evidence that

101 Our dosimetry data showed that a 370-MBq injection of (18)F-

102 brolizumab in vivo, while providing detailed dosimetry data that may lead to better dosing strategies

103 A-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has

104 d intravenous (18)F-FDG dosimetry with older dosimetry data.

105 Radiopharmaceutical dosimetry depends on the localization in space and time

106 Current standard values of fetal dosimetry deriving from (18)F-FDG injection in pregnant

107 study is to numerically assess the radiation dosimetry due to particles decaying in the respiratory t

108 (90)Y-PSMA-617 translates into a comparable dosimetry estimate and clinical findings similar to thos

109 Methods: A preliminary dosimetry estimate for (68)Ga-FAPI-2 and (68)Ga-FAPI-4 w

110 Here, we present our dosimetry estimate for (90)Y-PSMA-617, report first clin

111 A dosimetry estimate was calculated on the basis of time-a

112 (90)Y, and OLINDA was used to calculate the dosimetry estimate.

113 Dosimetry estimates for 1 MBq of (225)Ac-PSMA-617 assumi

114 Dosimetry estimates from OLINDA demonstrated that the or

115 Dosimetry estimates from OLINDA showed that the organs r

116 Dosimetry estimates indicate that the kidney is the dose

117 Toxicity studies in rats and human dosimetry estimates suggest that (64)Cu-Macrin is safe f

118 arance to assess lesion contrast and perform dosimetry estimates.

119 are required to achieve higher precision of dosimetry estimates.

120 pecific VIDA implementation enables tailored dosimetry estimation for regions most relevant in intrat

121 es were obtained at multiple time points for dosimetry estimation.

122 (124)I-omburtamab PET-based radiation dosimetry estimations revealed mean (+/-SD) absorbed dos

123 Similarly in the lungs, the %ID for all dosimetry-evaluable subjects was 4.9% at 15 min after in

124 inetic studies, radiometabolite studies, and dosimetry experiments.

125 The radiation dosimetry for (11)C-CNS5161 for a standard single inject

126 and tumors determined by (124)I PET/CT-based dosimetry for (131)I therapy of metastatic DTC when the

127 -CLR1404 (CLR 124) and estimated theranostic dosimetry for (131)I-CLR1404 (CLR 131) MRT in murine xen

128 y, we compared the human biodistribution and dosimetry for (18)F-FDG after oral and intravenous admin

129 The radiation dosimetry for (18)F-FETrp determined from the mouse data

130 y for diagnostic studies and for prospective dosimetry for (67)Cu-SARTATE peptide receptor radionucli

131 herein assess the cytotoxicity and radiation dosimetry for (68)Ga-NOTA-UBI and a first-in-human evalu

132 Results: The projected dosimetry for (90)Y-PSMA-617 estimated a mean kidney dos

133 omics) data, detailed metadata and radiation dosimetry for a variety of model organisms.

134 Subject-specific tumor dosimetry for CLR 131 MRT presents a correlative relatio

135 ulations to calculate subject-specific tumor dosimetry for CLR 131 MRT.

136 (64)Cu-LLP2A displayed favorable dosimetry for human studies and is a potential imaging c

137 ements in quantitative SPECT/CT, voxel-based dosimetry for radionuclide therapies has aroused growing

138 have aroused growing interest in voxel-based dosimetry for radionuclide therapies, because it promise

139 Dosimetry from multi-time-point PET imaging was performe

140 dict the average ADs after administration of dosimetry-guided (131)I activity.

141 with quantitative PET and SPECT imaging for dosimetry, have opened up exciting opportunities for rad

142 ed in the past, to propose a pathway whereby dosimetry helps the field by optimizing the biologic eff

143 ation, storm shelter concepts, and/or active dosimetry; however, the ever penetrating GCR will contin

144 he (18)F-FdCyd biodistribution and radiation dosimetry in 5 human subjects enrolled in companion ther

145 ted for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.

146 describe the clinical application of (124)I dosimetry in a patient who had radioiodine-refractory th

147 such as for (177)Lu-DOTATATE and for kidney dosimetry in different radiopharmaceuticals.

148 ssess safety, biodistribution, and radiation dosimetry in humans for the highly selective sigma-1 rec

149 Radiation dosimetry in mice indicated [(11)C]CPPC to be safe for f

150 PECT/CT imaging forms the basis for internal dosimetry in molecular radiotherapies.

151 Dosimetry in peptide receptor radionuclide therapy using

152 hallenges in performing routine personalized dosimetry in radiopharmaceutical therapies, interest in

153 Calculation of radiation dosimetry in targeted nuclear medicine therapies is trad

154 Calculation of radiation dosimetry in targeted nuclear medicine therapies is trad

155 ticular, we discuss the role of (124)I-based dosimetry in targeting of the sodium-iodine symporter an

156 Simplified personalized dosimetry in the clinic continues to be challenging.

157 t the compounds fulfill the prerequisite for dosimetry in the course of therapy planning with (67)Cu.

158 ow of the importance of in vitro and in vivo dosimetry in the hazard assessment and ranking of engine

159 udy was performed over 21 d to determine the dosimetry in tumors and normal tissue.

160 ety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of (18)F-tetra

161 col based on such a methodology for in vitro dosimetry, including detailed standardized procedures fo

162 rom MgO:Li,Ce,Sm has suitable properties for dosimetry, including high sensitivity to ionizing radiat

163 Because physical dosimetry indicated exposures to the nearby population o

164 dose model is preferred if ovarian radiation dosimetry is available.

165 Multiple-time-point SPECT/CT imaging for dosimetry is burdensome for patients and lacks statistic

166 la: see text] demonstrates that pretreatment dosimetry is particularly suitable for minimizing radiat

167 utical therapy (RPT) to specifically address dosimetry issues and strategies for future clinical tria

168 NJ-64413739 in healthy volunteers, including dosimetry, kinetic modeling, test-retest variability, an

169 We suggest routine dosimetry measurement of eye lens and proper protection

170 using a fixed constant of 1.8 for the planar dosimetry method and using the activity concentrations i

171 In the present work, we analyzed 2 STP dosimetry methods and evaluated dose errors for several

172 hen, dose accuracy was estimated using 2 STP dosimetry methods for a wide range of potential post inj

173 Conclusion: Simplified STP dosimetry methods may compromise the accuracy of dose es

174 values generated by the currently used blood dosimetry model correlated with RIF counts, the differen

175 tment, alpha-camera imaging, and Monte Carlo dosimetry modeling revealed DTCs both within and beyond

176 Dosimetry models using preclinical positron emission tom

177 Our results show that most dosimetry models were biased in their predicted clinical

178 18)F-labelled radiotracers using preclinical dosimetry models, different reconstruction methods and q

179 We also recommend dosimetry monitoring during the hemodialysis sessions pe

180 will significantly alter in vitro behavior (dosimetry, NP uptake, cytotoxicity), as well as in vivo

181 The STP framework was promising for dosimetry of (177)Lu-DOTATATE and for kidney dosimetry o

182 o biodistribution, were used to estimate the dosimetry of (177)Lu-NM600 treatments.

183 we determined the human whole-body and organ dosimetry of (18)F-clofarabine.

184 tudy was to evaluate the biodistribution and dosimetry of (18)F-FAZA in non-small cell lung cancer pa

185 erwent imaging to verify the human radiation dosimetry of (18)F-FTT.

186 e safety, feasibility, pharmacokinetics, and dosimetry of (18)F-MFBG in neuroendocrine tumors (NETs).

187 uate the administration safety and radiation dosimetry of (18)F-PSMA-11.

188 ety, biodistribution, and internal radiation dosimetry of (18)F-rhPSMA-7.3 are considered favorable f

189 Our objective was to model the cellular dosimetry of (64)Cu under different geometries commonly

190 the biodistribution, kinetics, and radiation dosimetry of (64)CuCl2 in humans and to assess the abili

191 tion, kinetics of the lesions, and radiation dosimetry of (64)CuCl2 were evaluated.

192 e biodistribution and estimate the radiation dosimetry of (68)Ga-ABY-025 for 2 different peptide mass

193 Methods: The biodistribution and dosimetry of (68)Ga-Tuna-2 was assessed by PET/CT in 13

194 -in-human study, we evaluated the safety and dosimetry of (89)Zr-pertuzumab PET/CT for human epiderma

195 to evaluate agreement between the predictive dosimetry of (99m)Tc-MAA SPECT/CT and posttreatment dosi

196 rimary aim of this study was to estimate the dosimetry of (99m)Tc-PSMA I&S using a hybrid method (seq

197 Methods: Dosimetry of (99m)Tc-PSMA I&S was investigated in 4 heal

198 e the tissue biodistribution and preliminary dosimetry of 2 members of this new class of PET radiopha

199 In this work, SPECT/CT-based voxel-level dosimetry of a 3-dimensional (3D) printed 2-compartment

200 In this work, SPECT/CT-based voxel-based dosimetry of a 3D printed 2-compartment kidney phantom w

201 d the safety, biodistribution, and radiation dosimetry of a novel (18)F-labeled radiohybrid prostate-

202 ed the whole-body distribution and radiation dosimetry of both radiotracers in humans.

203 dosimetry of (177)Lu-DOTATATE and for kidney dosimetry of different radiopharmaceuticals (errors < 30

204 dary standard systems for clinical reference dosimetry of electrons, therefore chamber response to th

205 condary standard ionisation chambers for the dosimetry of high dose-per-pulse VHEEs has been shown to

206 Dosimetry of organs and tumors helps to assess risks and

207 d the pharmacokinetics, biodistribution, and dosimetry of pembrolizumab in vivo, accomplished through

208 es a novel mechanism for trace detection and dosimetry of reactive gases.

209 her one can really use the former to predict dosimetry of the latter.

210 were extrapolated to humans to estimate the dosimetry of the tracer.

211 acquired with (86)Y-NM600, we estimated the dosimetry of therapeutic (177)Lu-NM600, which showed lar

212 Whole-body distribution and radiation dosimetry of this new probe were evaluated.

213 tolerability, biodistribution, and radiation dosimetry of this radiopharmaceutical.

214 tions are also discussed, including personal dosimetry of toxic industrial chemical, detection of exp

215 ycles without adjustment for peptide uptake, dosimetry, or radiobiologic and DNA damage effects in th

216 131)I therapy for the normal organs with the dosimetry package 3D-RD.

217 erapies, interest in single-time-point (STP) dosimetry, particularly using only a single SPECT scan,

218 antitative SPECT/CT imaging, a set of kidney dosimetry phantoms and their spherical counterparts was

219 on (TARE) using pretreatment partition model dosimetry (PMD).

220 Therefore, from a radiation dosimetry point of view, HD is preferred for PET/CT eval

221 nCl2 in mice, and performs preliminary human dosimetry predictions.

222 lasma free fraction of 38.5%, and a suitable dosimetry profile (effective dose of 20.5-24.5 muSv/MBq)

223 (68)Ga-Tuna-2 exhibited a safe dosimetry profile and no adverse events after intravenou

224 lects PARP expression and that its radiation dosimetry profile is compatible with those of agents cur

225 usion: (68)Ga-FAPI-46 PET/CT has a favorable dosimetry profile with an estimated whole body dose of 5

226 usion: (68)Ga-FAPI-46 PET/CT has a favorable dosimetry profile, with an estimated whole-body dose of

227 bes was conducted that included internal BPA dosimetry, progression to adenocarcinoma with aging and

228 ly applicable to the development of standard dosimetry protocols for VHEE radiotherapy, FLASH radioth

229 a reduced SPECT acquisition time in clinical dosimetry protocols.

230 ry techniques conventionally used in hepatic dosimetry provide a first-order estimate of absorbed dos

231 tine use of WB/BC dosimetry without lesional dosimetry provided no OS advantage when compared with em

232 tine use of WB/BC dosimetry without lesional dosimetry provided no OS advantage when compared with em

233 e retrospectively collected from the largest dosimetry provider in the United States for 49 991, 81 5

234 e addressed in clinical trials incorporating dosimetry-related concepts for determining the amount of

235 Partition-model predictive dosimetry relies on differential tumor-to-nontumor perfu

236 a, respectively), SPECT/CT-based voxel-level dosimetry resulted in mean absorbed doses of 3.0-6.6 Gy

237 (cortex/medulla), SPECT/CT-based voxel-level dosimetry resulted in mean absorbed doses ranging from 3

238 We present the first-in-humans radiation dosimetry results and biodistribution of (18)F-FdCyd, ad

239 After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) P

240 nts who require hemodialysis and details the dosimetry results obtained during treatment to ensure th

241 Safety dosimetry revealed kidney doses of approximately 0.75 Gy

242 In conclusion, the concept of voxel-based dosimetry should be treated with caution.

243 (177)Lu-NM600 dosimetry showed absorbed doses of 2.04 +/- 0.32 and 1.6

244 Dosimetry shows that conventional muCT usually does not

245 d 3 h after tracer injection using the QDOSE dosimetry software suit.

246 ted using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, v

247 mages of 5 insulinoma patients were used for dosimetry studies estimating the maximum insulinoma abso

248 overirradiation, we recommend pretherapeutic dosimetry studies for metastatic patients to calculate t

249 PET imaging, biodistribution, and dosimetry studies in mice, as well as immunohistochemica

250 Lastly, we performed dosimetry studies on rodents, from which we estimated th

251 istribution, pharmacokinetics, SPECT/CT, and dosimetry studies were performed to assess the bioequiva

252 Rodent dosimetry studies were performed to estimate the human-e

253 Tumor uptake, biodistribution, and dosimetry studies were performed to evaluate the efficac

254 s therefore not a surrogate for (90)Y-OPS201 dosimetry studies.

255 present a PET biodistribution and radiation dosimetry study of (68)Ga-FAPI-46 in cancer patients.

256 present a PET biodistribution and radiation dosimetry study of (68)Ga-FAPI-46 in cancer patients.

257 The dosimetry study provided an effective dose of less than

258 Lastly, a dosimetry study showed that the estimated effective huma

259 For the dosimetry study, the highest organ dose was in the liver

260 Eight patients were included for the tumor dosimetry study.

261 CTDIvol was estimated using the ImPACT CTDI dosimetry tables.

262 icrosphere distribution confirmed that (90)Y dosimetry techniques conventionally used in hepatic dosi

263 diatric clinical trials and provide detailed dosimetry that may lead to improved MRT treatment planni

264 the methodology and related tools have made dosimetry the optimum biomarker for RPT.

265 To perform voxel dosimetry, the SPECT/CT data and an in-house-developed M

266 ere imaged with (90)Y PET/CT for voxel-level dosimetry to determine lesion absorbed dose (AD) metrics

267 (131)I-omburtamab based on (124)I-omburtamab dosimetry to normal organs were low and well within tole

268 estimates for common organs in a preexisting dosimetry tool (OLINDA/EXM).

269 e an imaging agent and potential prospective dosimetry tool in 10 patients with neuroendocrine tumors

270 round state relaxation within the principal (dosimetry) trap.

271 an ovarian dose model with ovarian radiation dosimetry using logistic regression were selected.

272 nd recommendations for improved personalized dosimetry using simplified imaging schemes.

273 ent communication offers a revision of fetal dosimetry values calculated from recently published huma

274 Radiation dosimetry was acceptable, with effective doses of 9.5 mu

275 s analyzed for 11 organs using MIM software; dosimetry was assessed using OLINDA/EXM.

276 Radiation dosimetry was calculated using mouse biodistribution dat

277 ed dose per gram (%ID/g) was determined, and dosimetry was calculated using OLINDA/EXM, version 1.0.

278 Radiation dosimetry was calculated using the OLINDA/EXM software.

279 In advance of human studies, radiation dosimetry was determined in nonhuman primates.

280 es using pretherapeutic (124)I PET/CT lesion dosimetry was found.

281 ed using alpha-camera images, and microscale dosimetry was modeled.

282 Pretherapeutic (177)Lu-pentixather dosimetry was performed before (177)Lu-pentixather or (9

283 Methods: Whole-body dosimetry was performed in 3 healthy male subjects by co

284 Dosimetry was performed in 30 patients.

285 simplify and potentially automate radiation dosimetry we hope to accelerate the understanding of rad

286 Aiming at a simplification of dosimetry, we analyzed the accuracy of a theoretically s

287 Using these data to predict patient dosimetry, we found a kidney, pancreas, and liver exposu

288 simplify and potentially automate radiation dosimetry, we hope to accelerate the understanding of ra

289 The biodistribution and radiation dosimetry were assessed by serial whole-body PET/CT scan

290 Spatial distributions of internal radiation dosimetry were compared for different radionuclides ((13

291 curves were calculated, and organ uptake and dosimetry were estimated.

292 ring therapy, pharmacokinetics and radiation dosimetry were evaluated.

293 istribution, pharmacokinetics, and radiation dosimetry were performed on nonhuman primates.

294 ts, we evaluated with advanced 3-dimensional dosimetry whether improved minigastrin analog (177)Lu-DO

295 ted need for accurate radionuclide treatment dosimetry will likely drive the use of SPECT/CT in the n

296 (11)C-sarcosine showed a favorable radiation dosimetry with an effective dose estimate of 0.0045 mSv/

297 compared our detailed intravenous (18)F-FDG dosimetry with older dosimetry data.

298 e are questions about the reliability of STP dosimetry, with limited independent validations.

299 Routine use of WB/BC dosimetry without lesional dosimetry provided no OS adva

300 Conclusion: Routine use of WB/BC dosimetry without lesional dosimetry provided no OS adva